<DOC>
	<DOCNO>NCT00182871</DOCNO>
	<brief_summary>The purpose study assess effect testosterone replacement bone density , muscle strength , physical performance , quality life prostate symptom men select low bone mineral density fracture aspect frailty .</brief_summary>
	<brief_title>Testosterone Effects Bone Frailty</brief_title>
	<detailed_description>The hypothesis test testosterone supplementation increase bone mineral density specific parameter frailty old men osteoporosis characteristic frailty . One hundred eighty men , age 60 year old , sustain hip fracture fragility fracture follow mild moderate trauma ( fall stand height ) previous 5 year low femoral neck bone mineral density plus component frailty ( weight loss , perception exhaustion , physical strength , physical activity level walking time ) randomly assign receive either testosterone placebo , deliver topical gel apply daily , two year double-blind study . Bone mineral density ( BMD ) dual x-ray absorptiometry ( DXA ) , perform baseline yearly assess change BMD . Blood urine sample collect baseline yearly ; test correlate change BMD . To determine effect testosterone frailty , strength upper low extremity measure every 6 month use hand-held dynamometer sit leg press , respectively . Changes lean body mass percent body fat measure total body DXA baseline , 6 month annually . In addition , physical performance , emotional sexual function , disability assess also . The safety testosterone supplementation prostate cardiovascular parameter also monitor ; participant screen prostate cancer baseline , 6 month yearly 2 year . Fasting lipoprotein level measure yearly testosterone replacement , cardiovascular specific adverse effect angina , myocardial infarction , stroke sudden death tracked .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Men age 60 year sustain femoral fracture precede 3 year Total testosterone level 375 ng/dl bioavailable testosterone level least 1.5 SD low young adult mean Able come brought University Connecticut Health Center ( UCHC ) outpatient visit Prostate specific antigen level 4.0 ng/dl history prostate cancer Disease bone metabolism ( i.e. , Paget 's disease , osteomalacia , hyperparathyroidism ) History pituitary disease History sleep apnea Consumption 3 alcoholic drinks/day Use androgen , estrogen , DHEA precede year Use antiresorptive agent calcitonin bisphosphonates Metastatic advance cancer Current chemotherapy radiation treatment Plans move next three year Advanced liver renal disease subject unlikely complete three year intervention Hemaglobin &gt; 16.5 g/dl Bilateral hip replacement repair</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>geriatric medicine</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>HT</keyword>
	<keyword>andropause</keyword>
</DOC>